Consensus Hims & Hers Health, Inc.

Equities

HIMS

US4330001060

Market Closed - Nyse 04:00:02 2024-03-27 pm EDT 5-day change 1st Jan Change
15.74 USD -0.51% Intraday chart for Hims & Hers Health, Inc. -4.49% +76.85%

Evolution of the average Target Price on Hims & Hers Health, Inc.

Price target over the last 5 years

History of analyst recommendation changes

fe12f76cb979e5e4c3c39.NEmzeHvwtNcwGFaMYysvxqDYv1ck5XqjT8VH1rLqbyY.ZQvfEVaWhLF5dwa_DWdihMmHjGMXnSOWOY4L49yFKktTJdQBH5bc7mB0OQ~fd348ddb799f16984558d699f94ac791
Hims & Hers Health Insider Sold Shares Worth $823,055, According to a Recent SEC Filing MT
Tigress Financial Boosts Price Target on Hims & Hers Health to $19 From $15, Cites Move to Accelerated Growth Phase, Keeps Buy Rating MT
Piper Sandler Adjusts Price Target on Hims & Hers Health to $11 From $9, Maintains Neutral Rating MT
Deutsche Bank Adjusts Hims & Hers Health Price Target to $14 From $8, Maintains Hold Rating MT
Truist Securities Adjusts Price Target on Hims & Hers Health to $13 From $10, Keeps Hold Rating MT
Leerink Partners Initiates Coverage on Hims & Hers Health With Market Perform Rating, $10 Price Target MT
Tigress Financial Raises Price Target on Hims & Hers Health to $15 From $14, Maintains Buy Rating MT
Deutsche Bank Adjusts Hims & Hers Health Price Target to $8 From $11, Maintains Hold Rating MT
Truist Securities Cuts Price Target on Hims & Hers Health to $10 From $12, Maintains Hold Rating MT
TD Cowen Starts Hims & Hers Health at Outperform With $11 Price Target MT
Tigress Financial Adjusts Hims & Hers Health Price Target to $14 From $12 Due to Ongoing Growth, Penetration in Core Markets, Maintains Buy Rating MT
Tigress Financial Adjusts Hims & Hers Health Price Target to $14 From $12, Maintains Buy Rating MT
Piper Sandler Adjusts Price Target on Hims & Hers Health to $11 From $12, Keeps Neutral Rating MT
Deutsche Bank Adjusts Hims & Hers Health Price Target to $11 From $9, Maintains Hold Rating MT
BofA Securities Adjusts Hims & Hers Health's Price Target to $15 From $13.50, Keeps Buy Rating MT
Piper Sandler Adjusts Price Target on Hims & Hers Health to $12 From $10, Keeps Neutral Rating MT
Guggenheim Adjusts Price Target on Hims & Hers Health to $18 From $15, Maintains Buy Rating MT
Baird Initiates Hims & Hers Health at Neutral MT
Deutsche Bank Adjusts Hims & Hers Health Price Target to $9 From $7, Maintains Hold Rating MT
Credit Suisse Raises Hims & Hers Health's Price Target to $14 From $8 After Higher-Than-Expected Q4 Results, Keeps Outperform Rating MT
Piper Sandler Adjusts Price Target on Hims & Hers Health to $10 From $7, Maintains Neutral Rating MT
Truist Securities Adjusts Price Target on Hims & Hers Health to $12 From $7, Maintains Hold Rating MT
Citigroup Adjusts Price Target on Hims & Hers to $14 From $9, Keeps Buy Rating MT
BofA Securities Adjusts Price Target on Hims & Hers Health to $13.50 From $11.50, Maintains Buy Rating MT
Jefferies Upgrades Hims & Hers Health to Buy From Hold, Adjusts Price Target to $11 From $7 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
15.74 USD
Average target price
14.69 USD
Spread / Average Target
-6.69%
High Price Target
18 USD
Spread / Highest target
+14.36%
Low Price Target
7 USD
Spread / Lowest Target
-55.53%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Hims & Hers Health, Inc.

Tigress Financial
Deutsche Bank Securities
Piper Sandler
Truist Securities
Leerink Partners
TD Cowen
BofA Securities
Guggenheim
Baird
Credit Suisse
Citigroup
Jefferies & Co.
SVB Securities LLC
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
  1. Stock
  2. Equities
  3. Stock Hims & Hers Health, Inc. - Nyse
  4. Consensus Hims & Hers Health, Inc.